17,306 Shares in Ionis Pharmaceuticals, Inc. $IONS Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in the second quarter, Holdings Channel reports. The firm bought 17,306 shares of the company’s stock, valued at approximately $1,372,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IONS. Brown Brothers Harriman & Co. bought a new position in shares of Ionis Pharmaceuticals in the fourth quarter valued at approximately $27,000. Cassaday & Co Wealth Management LLC bought a new stake in shares of Ionis Pharmaceuticals during the 1st quarter worth $30,000. Quarry LP bought a new stake in shares of Ionis Pharmaceuticals during the 3rd quarter worth $38,000. Hilton Head Capital Partners LLC bought a new stake in shares of Ionis Pharmaceuticals during the 4th quarter worth $47,000. Finally, Laurel Wealth Advisors LLC acquired a new position in Ionis Pharmaceuticals in the 4th quarter valued at $47,000. Institutional investors and hedge funds own 93.86% of the company’s stock.

Insider Transactions at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP C Frank Bennett sold 5,536 shares of the firm’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $83.58, for a total value of $462,698.88. Following the sale, the executive vice president directly owned 75,018 shares in the company, valued at $6,270,004.44. This trade represents a 6.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Holly B. Kordasiewicz sold 362 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $84.30, for a total transaction of $30,516.60. Following the transaction, the executive vice president owned 22,096 shares in the company, valued at approximately $1,862,692.80. The trade was a 1.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 233,163 shares of company stock worth $18,316,551. 1.81% of the stock is currently owned by insiders.

Ionis Pharmaceuticals Stock Performance

Shares of IONS stock opened at $57.24 on Monday. Ionis Pharmaceuticals, Inc. has a 1 year low of $41.71 and a 1 year high of $86.74. The firm’s fifty day simple moving average is $65.62 and its 200 day simple moving average is $72.89. The firm has a market capitalization of $9.51 billion, a P/E ratio of -16.54 and a beta of 0.41. The company has a current ratio of 7.89, a quick ratio of 7.73 and a debt-to-equity ratio of 3.07.

Analyst Upgrades and Downgrades

IONS has been the topic of several recent analyst reports. Guggenheim dropped their target price on shares of Ionis Pharmaceuticals from $106.00 to $89.00 and set a “buy” rating on the stock in a report on Tuesday, July 21st. HC Wainwright lowered their price target on Ionis Pharmaceuticals from $125.00 to $115.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Wall Street Zen downgraded Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 1st. JPMorgan Chase & Co. lifted their price objective on Ionis Pharmaceuticals from $72.00 to $76.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Finally, Jefferies Financial Group cut their price objective on Ionis Pharmaceuticals from $113.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, July 9th. Eighteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ionis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $94.65.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.